A clinical comparison of how the FDA and EMA regulate Prometrium (micronized progesterone), including approval history, labeling differences, post-market surveillance, and prescribing implications for HRT.
A clinical review of Prometrium (micronized progesterone) regulatory approvals worldwide, including FDA history, EMA status, Health Canada authorization, label requirements, and post-market safety data.
FDA history of Prometrium (micronized progesterone), current label details, post-market safety data, and emerging next-generation progesterone delivery systems in clinical development.
A complete review of bremelanotide (Vyleesi) regulatory approvals, FDA labeling, global scheduling, and post-market safety data for hypoactive sexual desire disorder in premenopausal women.
Review of the current Vyleesi (bremelanotide, PT-141) label, effective November 2025, and the October 2026 supplement updating Section 8.
A clinical breakdown of rapamycin (sirolimus) compounding regulations, FDA approval history, label indications, and what patients need to know about legally obtaining compounded sirolimus for off-label use.
FDA approval timeline for Evenity (romosozumab), including the FRAME and ARCH trial context, the boxed warning for cardiovascular risk, label restrictions, and what remains unverified about post-market surveillance.
Evenity's current FDA label, effective July 16, 2026, carries a boxed warning for myocardial infarction, stroke and cardiovascular death.
How the FDA and EMA each regulate generic sildenafil, from bioequivalence standards and labeling differences to post-market surveillance frameworks. Evidence-based comparison for clinicians and patients.
A comprehensive regulatory guide to generic sildenafil covering FDA approval history, EMA authorization, global OTC reclassification, label requirements, and post-market safety surveillance data.
A clinical overview of generic sildenafil's regulatory history, current FDA-approved formulations, pipeline developments, and next-generation delivery systems for erectile dysfunction and pulmonary arterial hypertension.
A detailed review of FDA Adverse Event Reporting System (FAERS) data for generic sildenafil 20-100 mg, covering the most reported safety signals, serious adverse events, and what the post-market record means for prescribers and patients.
How the FDA and European regulators differ on spironolactone for acne, why neither has granted a formal indication, and what the evidence says about off-label prescribing.
A comprehensive review of spironolactone's regulatory status worldwide, including FDA approval history, off-label dermatologic use, EMA classification, and post-market safety surveillance data.
A clinical review of FDA label changes to spironolactone between 2020 and 2026, with specific focus on off-label acne use, safety warnings, and post-market surveillance findings.
A clinical review of suvorexant (Belsomra) regulatory history, patent litigation, FDA dose controversies, label restrictions, and post-market safety surveillance data.
A comprehensive review of tadalafil generic regulatory approvals worldwide, including FDA status, EMA authorization, safety labeling, and post-market surveillance data across major markets.
A detailed review of every FDA label update for generic tadalafil from 2020 through 2026, including revised cardiovascular warnings, NAION language, nitrate contraindications, and post-market safety signals.
Approved tadalafil forms and labeled uses: Cialis-type generic tablets, Alyq, Tadliq oral suspension and the Opsynvi combination tablet.
A guide to TB-500 (thymosin beta-4 fragment) regulatory status worldwide, including FDA classification, compounding pharmacy access, WADA prohibitions, and country-by-country legal standing.
How the FDA and EMA differ in their approval, labeling, and post-market surveillance of testosterone cypionate for hypogonadism and testosterone replacement therapy.
A complete timeline of FDA label updates for testosterone cypionate from 2020 through 2026, including cardiovascular warnings, abuse potential language, polycythemia alerts, and the impact of the TRAVERSE trial on prescribing.
A clinical review of testosterone cypionate's regulatory history, FDA label updates, post-market safety data from TRAVERSE, and the next-generation testosterone delivery systems in development.
A detailed review of testosterone enanthate's regulatory approvals, labeling requirements, and post-market safety monitoring across the FDA, EMA, TGA, and other global agencies.
Current legal status of compounded thymosin alpha-1 (thymalfasin) in the United States, including FDA classification, 503A pharmacy rules, and patient access pathways.
A country-by-country breakdown of thymosin alpha-1 (thymalfasin) regulatory status, including why it lacks FDA approval, where Zadaxin holds marketing authorization, and how US patients access it through compounding pharmacies.
A clinical review of thymosin alpha-1 (thymalfasin) regulatory changes from 2020 through 2026, including FDA classification, compounding pharmacy rules, and post-market safety data.
A clinical breakdown of thymosin alpha-1 (thymalfasin) legal status, FDA regulatory history, patent disputes, and current compounding pharmacy access rules in the United States.
Current FDA regulatory status of topical minoxidil, including OTC approval history, compounding legality under 503A and 503B, and what prescribers and patients need to know about compounded formulations.
A complete review of trazodone's regulatory history across FDA, EMA, and global agencies, including approval timelines, labeling updates, and post-market safety surveillance data.
A guide to tretinoin topical's FDA approval history, compounding regulations, labeling requirements, and current legal status for prescribers and patients.
A comprehensive review of every FDA label change for vaginal estradiol products from 2020 through 2026, including boxed warning revisions, new safety data, and clinical implications for prescribers and patients.
Complete FDA approval timeline for vardenafil, including Levitra film-coated tablets (2003), Staxyn ODT (2010), generic entry, label updates, and post-market safety data.
A comprehensive review of sildenafil (Viagra) regulatory status worldwide, including FDA approval history, EMA authorization, OTC reclassification in the UK, and ongoing post-market surveillance data.
Yes, lisdexamfetamine (Vyvanse) is a Schedule II controlled substance because it can be abused or lead to dependence. The FDA label has a boxed warning.
A clinical review of Wegovy's regulatory path, patent disputes, legal challenges from compounding pharmacies, and the evolving FDA label for semaglutide 2.4 mg.
Complete regulatory overview of Zepbound (tirzepatide) including FDA approval history, prescribing label details, EMA status, global availability, and post-market safety surveillance data.
Every FDA label change for Zepbound (tirzepatide) from initial approval through 2026, including new indications, boxed warning revisions, and post-market safety signals.
A clinical review of FDA Adverse Event Reporting System (FAERS) signals for Zepbound (tirzepatide), including GI events, gallbladder disorders, pancreatitis, thyroid warnings, and gastroparesis reports.
Rezdiffra dosing is set by body weight: 80 mg once daily under 100 kg and 100 mg once daily at 100 kg or more, with or without food.
Evidence-based guide to food and supplement interactions with Rezdiffra (resmetirom), the first FDA-approved therapy for MASH. Covers absorption effects, thyroid supplements, fiber timing, and clinical recommendations.
Rezdiffra's 2024 approval came with liver injury monitoring requirements; trial data shows diarrhea, nausea, and gallbladder events as the main risks so far.
How to store Rezdiffra (resmetirom) tablets, the FDA-labeled shelf life and temperature range, what a temperature or moisture excursion means for a specific bottle, and when to call a pharmacist instead of guessing.
TRICARE coverage for Rezdiffra (resmetirom) requires prior authorization and documented MASH diagnosis. Learn formulary tier, step therapy rules, appeal steps, and cost-saving options for military beneficiaries.
Which retatrutide studies enrolled adults, how STEP TEENS measured adolescent BMI, and what growth, puberty and safety questions remain unanswered.
What retatrutide trials show after 65—and what remains unknown about strength, falls, muscle loss, blood pressure, and medication safety.
Do retatrutide trials establish safety at ages 50–64? Audit GI events, body composition, cardiovascular evidence, and current FDA status.
Investigational retatrutide in pregnancy and lactation: class guidance versus absent human pregnancy, milk-transfer, fertility, and washout data.
Retatrutide safety evidence in young adults, separating adult trial eligibility from age-stratified adverse-event data and product-specific unknowns.
A clinical review of real-world Adderall XR user reports across Reddit, Drugs.com, and patient forums, weighed against what controlled ADHD stimulant trials have actually established.
A synthesis of real-world Adderall XR side-effect reports from Reddit, Drugs.com, and patient forums, with clinical trial context and practical guidance.
A review synthesis of real-world Adderall XR switching experiences from Reddit, Drugs.com, and patient forums, with clinical trial context and guidance on medication transitions.
What patient forums and drug-review sites say about switching to or from amlodipine for blood pressure, checked against what controlled trial evidence actually establishes.
What real AndroGel users report about side effects, from skin reactions and mood changes to cardiovascular concerns. Evidence-based review of patient experiences with testosterone gel.
Real-world patient experiences switching to and from AndroGel (testosterone gel 1% and 1.62%), including reasons for switching, timeline expectations, and clinical guidance on transitioning between TRT formulations.
An evidence-based review of AOD-9604 user reports, clinical trial data, and how this HGH fragment compares to FDA-approved fat-loss medications.
What real users report about AOD-9604 side effects across Reddit, forums, and clinical data. Injection-site reactions, headaches, GI symptoms, and what the limited evidence actually shows.
Generic atorvastatin is cheap at most US pharmacies and Tier 1 on most plans, while brand Lipitor costs far more. See real reported prices.
Real-world cost data, patient reviews, and clinical trial results for Vyleesi (bremelanotide) for HSDD. Includes out-of-pocket prices, insurance coverage patterns, and candid user experiences.
Real-world Farxiga (dapagliflozin) reviews synthesized from patient forums, clinical trial benchmarks, and user-reported outcomes for type 2 diabetes, heart failure, and CKD.